登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C21H30O3
化学文摘社编号:
分子量:
330.46
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
grade
certified reference material
Quality Level
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
drug control
psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)
concentration
100 μg/mL in methanol
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
cannabis testing
forensics and toxicology
format
single component solution
storage temp.
−20°C
SMILES string
OC1=CC(CCCCC)=CC2=C1C3C=C(CO)CCC3C(O2)(C)C
InChI
1S/C21H30O3/c1-4-5-6-7-14-11-18(23)20-16-10-15(13-22)8-9-17(16)21(2,3)24-19(20)12-14/h10-12,16-17,22-23H,4-9,13H2,1-3H3
InChI key
YCBKSSAWEUDACY-UHFFFAOYSA-N
General description
A Certified Spiking Solution® applicable in LC/MS or GC/MS applications for cannabinoid testing, urine drug testing, clinical toxicology, or forensic analysis. 11-Hydroxy-Δ9-THC is an active metabolite of THC and metabolic precursor to 11-nor-9-carboxy-Δ9-THC. This cannabinoid is found in biological matrices including urine, blood, and plasma.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under (±)-11-羟基-Δ9-四氢大麻酚标准液 溶液
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes,Central nervous system
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
监管及禁止进口产品
此项目有
Erin L Karschner et al.
Clinical chemistry, 57(1), 66-75 (2010-11-17)
Sativex(®), a cannabis extract oromucosal spray containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), is currently in phase III trials as an adjunct to opioids for cancer pain treatment, and recently received United Kingdom approval for treatment of spasticity. There are indications
Erin L Karschner et al.
Analytical and bioanalytical chemistry, 397(2), 603-611 (2010-03-23)
A sensitive analytical method for simultaneous quantification of sub-nanogram concentrations of cannabidiol (CBD), Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) in plasma is presented for monitoring cannabinoid pharmacotherapy and illicit cannabis use. Analytes were extracted from 1 mL plasma by
David A Gorelick et al.
Journal of clinical psychopharmacology, 31(5), 603-612 (2011-08-27)
Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ⁹-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| H-026-1ML | 04061833661864 |


